Clinical Trials
36 trialsPaclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
Ixabepilone to Treat Cervical Cancer
National Institutes of Health Clinical Center (CC)
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
National Cancer Institute (NCI)
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Advanced Cancers
National Cancer Institute (NCI)
BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
BMS 247550 to Treat Kidney Cancer
National Institutes of Health Clinical Center (CC)
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)